ArticleEuropean journal of drug metabolism and pharmacokinetics2022
Metabolic Profiling of Glabridin in Rat Plasma, Urine, Bile, and Feces After Intragastric and Intravenous Administration.
Article in European journal of drug metabolism and pharmacokinetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
- The antitumor mechanisms of glabridin and drug delivery strategies for enhancing its bioavailability.Frontiers in oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesGlabridin is usually used to treat cardiovascular and central nervous system diseases, which is a main bioactive phytoconstituent of licorice root. In this study, our aim was to obtain metabolic profiles of glabridin in rat plasma, urine, bile, and feces after intragastric and intravenous administration.
methodsBy UPLC-QTOF-MS, the metabolites of glabridin were systematically analyzed and identified. An ACQUITY UPLC HSS T3 column (100 × 2.1 mm, 1.8 mm) and the mobile phase containing water with 0.1% formic acid (A) and acetonitrile with 0.1% formic acid (B) via gradient elution was used as the chromatographic condition for separation. An extracted ion chromatogram strategy with multiple prototype/metabolite intermediate templates and 71 typical metabolic reactions was suggested to completely profile the metabolites of glabridin.
resultsFor the first time, 13 compounds in total were recognized from urine, plasma, bile, and feces of rats with the metabolite profiling strategy. The main metabolic form of glabridin in rats consisted of the prototype, hydroxylation, glucuronide conjugation, decarbonylation, and tert-butyl to alcohol metabolites.
conclusionsThe results not only indicated a comprehensive study on the probable metabolic pathways of glabridin in vivo, but also provided useful data and information for future pharmacological studies of glabridin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.